Valuation: Prenetics Global Limited

Market Cap 285M 249M 229M 213M 405M 27.13B 411M 2.75B 1.07B 13.33B 1.07B 1.05B 45.95B P/E 2026 *
-6.45x
P/E 2027 * -28.2x
Enterprise Value 285M 249M 229M 213M 405M 27.13B 411M 2.75B 1.07B 13.33B 1.07B 1.05B 45.95B EV / Sales 2026 *
1.4x
EV / Sales 2027 * 0.89x
Free-Float
85.39%
Yield 2026 *
-
Yield 2027 * -
1 day-5.37%
1 week-10.09%
Current month-11.45%
1 month-14.75%
3 months-13.97%
6 months+6.81%
Current year+7.49%
1 week 16.59
Extreme 16.59
19.46
1 month 16.59
Extreme 16.59
22.22
Current year 14
Extreme 14
23.63
1 year 7.18
Extreme 7.175
23.63
3 years 2.85
Extreme 2.85
23.63
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 01/01/2014
Chief Executive Officer 47 01/01/2014
Director of Finance/CFO 41 01/01/2018
Director TitleAgeSince
Director/Board Member 60 13/06/2024
Chairman 47 01/01/2014
Director/Board Member - 16/02/2026
Date Insider Type Main position Quantity % Market Cap.
15/06Fiscal year

Director

31,746 0.2082%
15/06Fiscal year

Director

15,625 0.1025%
04/06Other

Director

24,004 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-5.37%-10.09%+111.62%+28.21% 285M
+3.49%+1.36%-29.04%-11.15% 166B
+5.04%+2.73%-5.88%-4.24% 106B
+2.80%+3.63%+0.09%+55.53% 57.69B
-1.37%-0.89%+54.58%+57.19% 53.78B
+3.39%+1.39%-10.26%-39.27% 43.56B
+3.50%+11.11% - - 36.52B
+3.47%+1.58%-14.08%-44.37% 27.49B
+0.20%+4.24%+64.56%-2.99% 25.84B
+2.78%+1.17%-8.15%-0.33% 21.27B
Average +1.79%+2.78%+18.16%+4.29% 53.91B
Weighted average by Cap. +3.04%+3.79%-3.62%+1.93%

Financials

2026 *2027 *
Net sales 203M 177M 163M 152M 288M 19.32B 293M 1.96B 761M 9.5B 762M 745M 32.73B 319M 279M 257M 239M 453M 30.4B 460M 3.08B 1.2B 14.94B 1.2B 1.17B 51.49B
Net income -48.71M -42.58M -39.13M -36.48M -69.19M -4.64B -70.24M -470M -183M -2.28B -183M -179M -7.86B -9.62M -8.41M -7.73M -7.2M -13.67M -916M -13.87M -92.8M -36.07M -450M -36.11M -35.34M -1.55B
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
02/07/26 USD 16.93 -5.37% 122,280
01/07/26 USD 17.89 -6.43% 65,868
30/06/26 USD 19.12 +2.91% 61,082
29/06/26 USD 18.58 -1.33% 86,049
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
16.93USD
Average target price
31.00USD
Spread / Average Target
+83.11%

Quarterly revenue - Rate of surprise